What information is required in the Prescription Drug Data Collection (RxDC) Report under Section 204 of Division BB, Title II (Section 204) of the Consolidated Appropriations Act, 2021 (CAA)?

The report includes general information identifying the insurer or plan as follows:

• Enrollment and premium information, including average monthly premiums paid by employees and the employer
• Total health care spending, broken down by type of cost (e.g., hospital care, primary care, specialty care, prescription drugs, and other medical costs including wellness services) by enrollees and by employer or insurer
• Prescription drug spending by enrollees and employers or insurer
• 50 most frequently dispensed brand prescription drugs
• 50 costliest prescription drugs by total annual spending
• 50 prescription drugs with the greatest increase in plan or coverage expenditures from the prior year
• Prescription drug rebates, fees, and other remuneration paid by drug manufacturers to the plan or issuer in each therapeutic class of drugs, as well as for each of the 25 drugs that yielded the highest amount of rebates
• Impact of prescription drug rebates, fees, and other remuneration paid by prescription drug manufacturers on premiums and out-of-pocket costs

As required, reporting will be aggregated at the state/market level, rather than separately for each plan. As such, each group’s data except its identifying information is not identifiable within the report and cannot be pulled out from the submission. The federal guidance provides uniform standards and definitions, including standards for identifying prescription drugs regardless of the dosage strength, package size, or mode of delivery. There are uniform standards for submitting data that are intended to allow the Tri-Agencies and US Office of Personnel Management (OPM) to conduct meaningful data analysis and identify prescription drug trends. More information can be found in the Prescription Drug Data Collection (RxDC) Reporting Instructions (PDF).